MiNK Therapeutics Reports Landmark Case of Complete Remission in Testicular Cancer Patient.

MiNK Therapeutics announced the publication of a landmark case in Nature's Oncogene describing a patient with metastatic testicular cancer who achieved complete and durable remission after treatment with agenT-797, an allogeneic iNKT cell therapy. The patient had failed multiple lines of therapy, including platinum-based chemotherapy, autologous stem cell transplant, and multiple immune checkpoint inhibitors. The case highlights the potential of MiNK's allogeneic iNKT cell therapy as a salvage treatment option for patients with heavily pre-treated germ cell tumors.

MiNK Therapeutics, Inc. (NASDAQ: INKT) recently announced a significant milestone with the publication of a landmark case in Nature's Oncogene. The study details a patient with metastatic testicular cancer who achieved complete and durable remission following treatment with agenT-797, an allogeneic invariant natural killer T (iNKT) cell therapy [1].

The patient had previously failed multiple lines of therapy, including platinum-based chemotherapy, autologous stem cell transplant, and multiple immune checkpoint inhibitors (anti–PD-1, anti–CTLA-4, and anti–TIGIT) [1]. Despite these treatments, the patient received a single infusion of agenT-797 alongside nivolumab, resulting in a complete clinical, radiologic, and biochemical remission that has persisted for over two years [1].

This case underscores the potential of MiNK's allogeneic iNKT cell therapy as a salvage treatment option for patients with heavily pre-treated germ cell tumors. The therapy demonstrated remarkable safety, with no cytokine release syndrome or graft-versus-host disease observed [1].

MiNK has presented promising Phase 2 trial data in gastric cancer, showing extended survival beyond 12 months in several patients and a separate case reporting 42% tumor reduction and nine months of progression-free survival following a single infusion of agenT-797 in combination with nivolumab [1].

The persistence of donor cells for six months post-infusion may explain the durability of the response, suggesting these cells effectively reshape the tumor microenvironment to overcome prior treatment resistance [1]. While a single case cannot establish efficacy across broader populations, this complete remission in such a challenging context provides compelling rationale for expanded clinical development of iNKT cell therapies in solid tumors where treatment options remain limited [1].

References:
[1] https://www.globenewswire.com/news-release/2025/07/11/3113929/0/en/MiNK-Therapeutics-Announces-Publication-of-Complete-Remission-Following-Allogeneic-iNKT-Cell-Therapy-in-Metastatic-Testicular-Cancer.html